Recurrent Follicular Lymphoma
Showing 1 - 23 of 23
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in United States (Bendamustine
Suspended
- Grade 1 Follicular Lymphoma
- +4 more
- Bendamustine Hydrochloride
- +13 more
-
Anchorage, Alaska
- +422 more
Feb 2, 2023
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle
Not yet recruiting
- Post-Transplant Lymphoproliferative Disorder
- +10 more
- Loncastuximab Tesirine
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +4 more
May 10, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)
Completed
- Mantle Cell Lymphoma
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Jan 18, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
CD19 Positive, Mantle Cell Lymphoma, Recurrent DLBCL Trial in Houston (procedure, drug, biological)
Withdrawn
- CD19 Positive
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2020
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in United States (procedure, drug,
Completed
- Acute Lymphoblastic Leukemia
- +25 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Aurora, Colorado
- +5 more
Dec 17, 2019
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma Trial in ChongQing
Unknown status
- Recurrent Adult Diffuse Large Cell Lymphoma
- +8 more
- CD19.CAR-T cells
-
ChongQing, Chongqing, ChinaDepartment of Oncology
Feb 25, 2019